Anti-thymocyte Globulin Therapy for Cases of Acute Rejection Following Lung Transplantation

A 58-year-old male underwent right lung transplantation from a brain-dead donor, after which acute rejection developed that was resistant to steroid pulse therapy. Rabbit-derived anti-thymocyte globulin (rATG) therapy was successful for controlling the rejection. However, following that therapy, the...

Full description

Saved in:
Bibliographic Details
Published inKyobu geka. The Japanese journal of thoracic surgery Vol. 69; no. 11; p. 906
Main Authors Karube, Yoko, Ito, Yoshiyuki, Nishihira, Morimichi, Inoue, Takashi, Araki, Osamu, Maeda, Sumiko, Kobayashi, Satoshi, Chida, Masayuki
Format Journal Article
LanguageJapanese
Published Japan 01.10.2016
Subjects
Acute Disease
Animals
Antilymphocyte Serum - therapeutic use
Graft Rejection - immunology
Humans
Lung Transplantation
Male
Middle Aged
Rabbits
Thymocytes - immunology
Tomography, X-Ray Computed
Online AccessGet more information

Cover

More Information
Summary:A 58-year-old male underwent right lung transplantation from a brain-dead donor, after which acute rejection developed that was resistant to steroid pulse therapy. Rabbit-derived anti-thymocyte globulin (rATG) therapy was successful for controlling the rejection. However, following that therapy, the patient was affected by an opportunistic infection and suffered from repeated empyema. It is important to pay attention to immunosuppressive agent levels in blood following treatment, because ATG is a potent immunosuppressive drug and its effects can continue for more than 6 months after administration.
ISSN:0021-5252